Menu Menu

News

Featured
COVID-19 Research Pipeline

90,466

Registered/ Published

3,540

Registered

464

Published

5,414

Registered
As at 14 October 2021
FILTERED BY > Convalescent plasma Clear filter

Communique # 48

5 August, 2021
WEEK IN REVIEW Taskforce amends remarks for Tocilizumab in response to critical shortage This week the Taskforce was alerted by the Therapeutic Goods Administration (TGA) to a global tocilizumab shortage for both COVID-19 treatment use and other indications. To help support the TGA’s efforts to conserve supply, the Taskforce has revised the remarks section of the tocilizumab for adults recommendation to reflect: the second dose of...
Communique

Guidelines update, v41.1

15 July, 2021
Version 41.1 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of six new studies on disease-modifying treatments. Convalescent plasma - two...
News

Guidelines update, v38.3

13 May, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include the following changes to the evidence summary sections for:   Convalescent plasma...
News

Guidelines update, v38.1

29 April, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include the following changes to the evidence summary sections for:   - Lopinavir-ritonavir...
News

Communique # 41

1 April, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Convalescent plasma recommendation changed to 'do not use' The Taskforce Disease Modifying and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated...
Communique

Guidelines update, v35.2

11 March, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include:   Tocilizumab - The reference for one included study (Wang et al.) was...
News

Guidelines update, v35.1

4 March, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include: Tocilizumab - The references for REMAP-CAP and COVACTA (Rosas et al.) trials have...
News